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he Frustrating Search for
rrhythmia Risk Stratifiers
n Heart Failure Due to
onischemic Cardiomyopathy
oes T-Wave Alternans Testing Help?*
ichard L. Verrier, PHD, FACC,
apil Kumar, MD,
ark E. Josephson, MD, FACC
oston, Massachusetts
dentification of heart failure patients who are at risk for
ife-threatening arrhythmias due to cardiomyopathy has
een challenging, particularly for those without underlying
oronary artery disease. The inherent complexity of risk
tratification in this group is probably attributable to mul-
ifactorial changes in myocardial substrate and disruption in
utonomic function. Risk identification in patients with this
iagnosis is a pressing problem, because this condition
ccounts for 10% of adult sudden cardiac deaths (SCDs)
nd is associated with an annual mortality rate of 10%. The
tility of electrophysiologic testing in these patients has
roved to be limited, but signal-averaged electrocardio-
rams (ECGs) and depressed heart rate variability are
otentially useful. Guiding therapy, including use of poten-
ially life-saving implantable cardioverter-defibrillators
ICDs), is an important goal that must be performed
eliably, because the devices carry risk with respect to
nfection, lead complications, and inappropriate delivery of
herapy.
See page 1896
T-wave alternans (TWA) testing has been shown in-
reasingly to be useful in diverse patient populations using
oth the traditional spectral method (1) and the time-
omain modified moving average approach, which can be
mplemented during routine exercise testing (2). With
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.N
From the Cardiovascular Institute, Beth Israel Deaconess Medical Center, Harvard
edical School, Boston, Massachusetts.espect to nonischemic cardiomyopathy, the TWA litera-
ure is less extensive and the results have been mixed (3–6).
he Current Study
n this issue of the Journal, Salerno-Uriarte et al. (7) present
he results of the ALPHA (T-Wave ALternans in Patients
ith Heart fAilure) study. The main objective of this
ulticenter, prospective, observational study was to assess
he predictive utility of TWA in patients with New York
eart Association (NYHA) functional class II and III heart
ailure of nonischemic etiology with left ventricular ejection
raction (LVEF)40%. The study enrolled 446 consecutive
nselected patients, the majority of whom had a diagnosis of
diopathic dilated cardiomyopathy. T-wave alternans was
nalyzed during exercise stress testing using the spectral
ethod, and patients were followed for a median of 19
onths.
This study adds importantly to our current understanding
f TWA testing, because it is 1 of the largest studies in
atients with nonischemic cardiomyopathy. Patient
ollow-up was excellent. A large majority (80%) of pa-
ients were receiving a contemporary heart failure medi-
ation regimen, which consisted of beta-blockade,
ngiotensin-converting enzyme inhibition, and diuretics,
nd one third were taking aldosterone antagonists as well.
hese medications were continued at the time of testing,
nlike in some TWA studies (3), in which beta-blockade
as withheld before testing. The ALPHA study demon-
trated that patients with abnormal (non-negative) TWA
est results had an adjusted hazard ratio (HR) of 3.2 for the
ombined primary end point of cardiac death and life-
hreatening arrhythmias. This yielded a negative predictive
alue (NPV) of 97.3% at 18 months but a positive predictive
alue of only 9%.
A potential limitation is the relatively low event rate, with
-year all-cause mortality of 4.2%, compared with 6.2% in
he DEFINITE (Defibrillators in Nonischemic Cardiomy-
pathy Treatment Evaluation) trial (8). The authors argue
hat this difference is attributable to inclusion of patients
ith higher LVEF (mean 29.5% vs. 21.4%) and exclusion of
atients with atrial fibrillation and ambient ventricular
rrhythmia. They suggest that if these proven risk factors
re considered, the event rate of the ALPHA study would
e comparable to that of existing studies in patients with
onischemic cardiomyopathy.
Controversy has been raised regarding the prognostic
apacity of TWA in patients with left bundle branch block.
n the ALPHA study, where 42.6% of patients had left
undle branch block, QRS duration had a minimal effect on
he NPV of TWA testing. Similarly, the adjusted HR
emained significant at 3.91 with an NPV of 96.8% at 18
onths, even when only patients with LVEF 35% were
nalyzed. This subgroup analysis is instructive, because even
n patients with a presumed higher arrhythmic risk, the
PV of TWA remains persuasive.
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Editorial Comment November 6, 2007:1905–6Evidence conflicting with the results of the ALPHA
tudy has been reported from a substudy of the SCD-
EFT (Sudden Cardiac Death in Heart Failure Trial) (5),
hich investigated TWA in 490 patients with LVEF35%
nd NYHA functional class II and III symptoms. The
CD-HEFT substudy failed to demonstrate the capacity of
WA testing to predict the composite primary end point of
CD, sustained ventricular arrhythmia, or appropriate ICD
ischarge. Some key differences between these 2 studies
nclude a 41% indeterminate rate (compared with 20.6% in
he ALPHA study), the inclusion of ischemic cardiomyop-
thy, and an LVEF cutoff of 35%. A more thorough
omparison awaits the full-length publication.
Notwithstanding a number of positive observational stud-
es, a critical piece of evidence will be the demonstration in
randomized clinical trial that TWA contributes to guiding
CD implantation. The results of the ABCD (Alternans
efore Cardioverter Defibrillator) trial, which was designed
or this purpose, await publication (9).
onclusions
he sizable ALPHA study represents a significant step
orward in arrhythmia risk stratification of patients with
eart failure due to nonischemic cardiomyopathy. The
esults are encouraging with respect to identifying patients
ho are unlikely to benefit from an ICD. There is a need to
mprove the positive predictive value of TWA test results,
hich, in the 9% range, was relatively low.
An attractive strategy is to depart from the current binary
pproach of classifying test results either as “abnormal” or
normal/negative” and to reconsider the potential value of
uantitative assessment of TWA. Klingenheben et al. (4)
emonstrated that patients with heart failure due to dilated
ersus ischemic cardiomyopathy and those with ventricular
achyarrhythmias exhibited higher TWA levels. They pro-
osed that quantitative TWA assessment may provide
dditional pathophysiologic insights and prognostic infor-
ation over qualitative binary TWA test classification. This
pproach is consistent with recommendations from our
roup (10).
Also, because this diagnosis includes multiple pathologies
ith derangements in myocardial substrate and varying
egrees of altered autonomic function, a multiparameter
pproach including LVEF could prove useful. Ambulatory
CG analysis offers the intrinsic advantage of TWA testing
11,12) in combination with autonomic function by heart
ate turbulence (13). This surmise could be tested in the
LPHA study, because 24-h ambulatory ECG monitor-ng was part of the protocol. These new tools offer
onsiderable promise in dealing with the intrinsic com-
lexities of nonischemic cardiomyopathy. Although con-
iderable progress has been made by the present and
arlier studies, a major missing element remains, namely,
andomized clinical trials evaluating the utility of TWA
n guiding therapy.
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